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1. Introduction
The skin is the largest organ of the body with many different functions as thermoregulation,
immune protection, sensory perception, vitamin D production and it acts as a barrier be‐
tween the animal and the environment. Besides all of these important functions and the dis‐
eases that affect directly the skin, it may also share or reflect pathologic processes from other
tissues. Due to these characteristics, dermatologic problems are among the most commonly
seen disorders in veterinary hospitals. It is important for the veterinarian to know and un‐
derstand about the physiology of the skin and about the most common dermatologic disor‐
ders that affects dogs and cats, which will be addressed in this chapter.
2. Skin structure
The skin is divided in three layers: epidermis, dermis and hypodermis (Figure 1). Epider‐
mis, the outermost layer of the skin, is composed by keratinocytes, melanocytes and Langer‐
hans cells. Keratinocytes are also disposed in layers in the epidermis. The deepest one, the
stratum basale, is formed by a single row of germinative keratinocytes and also contains
melanocytes. These germinative keratinocytes generate the other layers by cell division and
differentiation. The next layer, stratum spinosum, differs from stratum basale by the pres‐
ence of intercellular junctions. Langerhans cells are also present in this layer. Stratum granu‐
losum is characterized by a large amount of keratohyaline granules inside keratinocytes
which are important in the skin keratinization process. Stratum corneum, the outer epider‐
mis layer, is composed by keratinocytes in their maximal differentiation degree (corneo‐
cytes), interspersed in lipid matrix [1].
© 2013 Bourguignon et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Dermis, the layer under the epidermis, is composed by a conjunctive matrix where reticular,
elastic and collagen fibers are found. Dermis cellular structure is composed by fibroblasts,
mast cells and histiocytes. It also contains epidermal appendages (hair, nails, sebaceous and
sweat glands), arrector pili muscles and blood and lymph vessels. Hypodermis or subcuta‐
neous tissue provides support and cushioning against physical trauma. It is composed by a
loose connective tissue and elastic fibers interspersed by adipocytes [1]. The hair follicles ex‐
hibit activity cycles that result in hair formation. Anagen is a period of active growth when a
new hair is being formed. Catagen is when the hair growth stops and degenerative changes
occur in the base of the follicle. Telogen represents a period of follicle inactivity, when the
hair is shed so that a new one may start to grow [1]. Hair cycle activity, in some dog breeds,
is strongly related to temperature variation and photoperiod, leading to decreased hair den‐
sity in the warmer months, which helps the heat loss in these animals [2].
Figure 1. Structure of the skin.
3. Diagnosis techniques
Diagnosis approach for skin diseases depends on obtaining detailed history with thorough
physical and dermatological examination. The evaluation offers precious information and
guides the investigative process. Specific tests and, occasionally, therapeutic trials should be
performed [3].
Skin scrapings, trichogram, fungal and bacterial culture, cytological evaluation and skin bi‐
opsy are important diagnosis techniques in dermatology. Skin scrapings are applied in mite
detection, and it may be superficial or deep depending on the mite that is suspected. The
sample obtained is evaluated under optical microscopy [3]. Fungal culture is recommended
for patients that fungal diseases are suspected. Hair samples and skin scales should be col‐
lected from the lesion margin. Bacterial culture is not often performed and it is recommend‐
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ed in pyoderma refractory to initial therapy or when rods are observed in cytology [4]. The
direct examination of the hairs, the trichogram, is performed by pulling the hairs from the
affected area, followed by microscopic evaluation. With this technique it is possible to deter‐
minate hair growth phase abnormalities and the presence of follicles parasites and dermato‐
phytes [3]. Cytology is the analysis of tissue cells and it is a highly efficient and valuable
exam to evaluate a lesion, after which it is possible to establish the next step in the diagnos‐
tic approach. The sample may be obtained by fine-needle aspiration, swab, skin scrapings or
lesion imprint [5]. Histopathology associated with clinical findings usually leads to defini‐
tive diagnosis. Skin biopsy is recommended in unusual lesions, possibly neoplastic nodules,
dermatosis with expensive therapy or when it represents a risk to the patient health, with
poor response to previous therapy and to exclude differential diagnoses [4]. To perform the
histopathological exam at least three representative samples should be obtained by punch or
surgical resection [3].
4. Bacterial skin diseases
Pyoderma is a bacterial skin infection and it is among the most common causes of skin dis‐
eases in dogs [6], however, it is less common in cats [7]. Lesions may be superficial and in‐
volve only the epidermis or they may affect deeper structures in the dermis or subcutaneous
tissue, and it is therefore divided into surface, superficial and deep pyoderma [6]. Staphylo‐
coccus pseudintermedius is the most commonly isolated bacteria from dog’s skin [8] and it is
among the main reasons for antimicrobial use in these animals [9].
Surface pyodermas are characterized by superficial erosions of the stratum corneum. The
presence of alopecia, erythema and pruritus are common findings [10]. Intertrigo is a surface
pyoderma that affects the skin folds found in lips, face, vulva, tail and mammary glands of
some breeds, and it may also affect the skin folds of obese animals. Acute moist dermatitis,
also known as pyotraumatic dermatitis or hot spots, is of acute onset and rarely occurs as a
primary disease in healthy skin, being usually secondary to other diseases [11]. Probably, lo‐
cal irritation due to an underlying cause leads to self-inflicted trauma, which quickly be‐
comes extensive areas of skin damage [10].
Superficial pyodermas are the most common causes of cutaneous bacterial infection in dogs
[6]. They affect the superficial portion of the hair follicles (bacterial folliculitis) or the epider‐
mis (impetigo), causing pustules [10, 11]. The most common lesions are crusted papules due
to the transient nature of canine pustules. Pruritus, epidermal collarettes, hyperpigmenta‐
tion and alopecia are also common findings [6]. Impetigo affects sexually immature dogs
that may present subcorneal pustules formed in inguinal and axillary areas [10]. Superficial
bacterial folliculitis is the most common form of pyoderma in dogs [12]. Papules, pustules
associated with hair follicles, epidermal collarettes, alopecia and hyperpigmentation are
commonly found [10] (Figure 2).
Deep pyoderma does not occur spontaneously, often starting as superficial pyoderma [6].
Other organisms such as Proteus spp., Pseudomonas spp. and E. coli may be involved [12-14].
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The bacterial infection affects the deepest portion of the hair follicle (deep folliculitis), that
may lead to follicular wall rupture and to bacterial product release in the dermis (furunculo‐
sis), or it can also affect the deeper portion of the dermis and subcutaneous tissue (cellulitis)
[10, 15]. The affected skin appears erythematous, hyperpigmented, with the presence of se‐
ropurulent debris from the ruptured pustules; variable pruritus, swelling, skin stiffness and
evident pain are also noted [6].
Diagnosis is obtained through the evaluation of clinical signs, presence of characteristic skin
lesions, elimination of other possible causes of folliculitis and by cytological evaluation of
the intact pustules content, exudative lesions and skin debris. In the management of pyoder‐
ma, it is important to identify the possible underlying disorder, which may be done through
skin scrapings, scabies therapeutic trial, allergy tests, endocrinopathies screenings, hypoal‐
lergenic diet trials, strict ectoparasites control and skin biopsies. [16].
The treatment varies depending on presented lesions. Local surface and superficial pyoder‐
mas may be treated only with topical antibiotics such as silver sulphadiazine, neomycin or
2% mupirocin ointments applied twice daily over the affected areas. Generalized lesions and
deep pyodermas require a combination of oral and topical antibiotics. In patients with se‐
vere pruritus it is recommended to use anti-inflammatory doses of prednisone orally for up
to two weeks [17]. The antibiotics of choice for oral use include cephalexin (22-33 mg / kg
q12h) and amoxicillin associated with clavulanic acid (22 mg/kg q12h) [18]. Recurrent cases
require culture and susceptibility testing to access resistance [16].
Figure 2. Superficial bacterial folliculitis in a Dachshund. Multiple areas of alopecia and erythema are seen in the
trunk area.
5. Fungal diseases
5.1. Dermatophytosis
Dermatophytosis is a superficial mycosis caused by Microsporum, Trichophyton or Epidermo‐
phyton fungi genera. These fungi are isolated from hair, nails and skin surface since they
Insights from Veterinary Medicine6
require keratin for their growth [19]. Dermatophytes are classified into three groups based
on their habitat: zoophilic, mostly found in animals, occurring transmission to other ani‐
mals  or  to  humans;  anthropophilic,  mostly  found  in  humans,  transmitted  between  hu‐
mans  and  rarely  to  animals  and  geophilic,  dermatophytes,  found  in  the  soil,  infects
humans and animals [20]. M. canis  is the most frequently isolated fungal species in dogs
and cats [21].
Clinically, canine and feline fungal infections differ. Infections in dogs often produce le‐
sions, while it is possible to isolate dermatophytes from clinically healthy cats, which can act
as a conidia reservoir of the fungus [22]. The affected animals usually have alopecic, scaly,
crusted, erythematous and papular lesions, especially in the face and limbs. Occasionally,
dermatophytes may be presented in a nodular form known as kerions. This form of derma‐
tophytosis is characterized by deep, inflammatory and suppurative lesions [23]. Pruritus
may vary from absent to severe [24].
The direct microscopic examination of hairs and scales can reveal the presence of fungal hy‐
phae or spores. The fungal culture is the diagnostic test of choice and the sample may be
obtained by brushing the animal with a toothbrush or by skin scrapings [25].
The best strategy for the treatment of dermatophytes is the association of systemic and topi‐
cal antifungal therapy. The aims of the treatment with topical products are the elimination
of the fungi present at the epidermis and hair surface, while systemic treatment aims to
eliminate infection within the hair shafts [26]. Lime sulfur rinse at 6.5 % twice a week
showed good results in cats infected with M. canis [27, 28]. Systemic treatment options in‐
clude itraconazole orally at 10 mg/kg once a day, griseofulvin 50 mg/kg once a day or terbi‐
nafine 5 mg/kg once a day [27-29]. The treatment must be extended over 2 to 4 weeks after
clinical cure and after obtaining two or more negative fungal cultures [23].
5.2. Malassezia dermatitis
Malassezia pachydermatis is a commensal skin yeast, commonly isolated from lips, interdigital
skin, anal mucosa and external auditory canal [30]. It is an opportunistic yeast, which usual‐
ly manifests itself after the installation of other diseases. It is very common in dogs and least
frequent in cats [31]. Previous antibiotic therapy is associated with the development of cuta‐
neous M. pachydermatis over growth in dogs [32], as well as disorders of keratinization and
hypersensitivity diseases [33]. Basset Hounds, Cocker Spaniels and West Highland White
Terriers are more predisposed to this type of infection [32].
The most common clinical manifestation of Malassezia dermatitis is the presence of moderate
to intense pruritus [34]. Erythema, lichenification, oily skin, malodor, alopecia and erosions
are also common clinical findings [35] that can be generalized or localized [34].
Cytology is the diagnostic method of choice and allows microscopic identification of the in‐
creased number of yeasts. Samples can be obtained by skin scrapings, swabs, direct imprint
or by tape preps. Fungal culture is not recommended as a diagnostic procedure because it is
not a quantitative assessment [36].
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Identification and correction of the predisposing diseases are essential for the successful
treatment of Malassezia dermatitis [23]. Mild cases can be treated with miconazole, chlorhexi‐
dine, ketoconazole or acetic acid shampoos. Baths should be given, two times per week, for
a minimum of six weeks [36]. Patients requiring systemic treatment should receive oral anti‐
fungals such as ketoconazole, itraconazole or fluconazole 5 mg/kg once a day for a mini‐
mum of 30 days [36]. Terbinafine 30 mg /kg every 24 hours on two consecutive days in a
week, for six weeks, may also be an effective treatment [37]. In order to prevent recurrences
of the disease, regular maintenance therapy may be needed in many dogs [23].
5.3. Sporotrichosis
Sporotrichosis is a subcutaneous mycosis caused by a dimorphic fungus, Sporothrix schenckii,
which can infect animals and humans [39]. It is a zoonotic disease and transmission to hu‐
mans occurs through bites or scratches, and contact with cats ulcers [40]. S. schenckii is
present in the decaying vegetation and soil and animal contamination occurs by skin open
lesions such as perforations, bites and scratches. Once in the host organism, the fungus may
cause local lesions and possibly systemic signs [41].
Clinically, sporotrichosis has three forms: cutaneous, lymphocutaneous and generalized,
and more than one form can occur simultaneously in the same animal. The cutaneous form
is usually confined to the area of fungus inoculation and manifests after an incubation peri‐
od of one month. If this lesion is not treated, the progression to lymphocutaneous form can
occur. The lymphocutaneous form is characterized by the development of nodules that
evolve into ulcers, affecting skin, subcutaneous tissue, lymph vessels and regional lymph
nodes [41]. History of lethargy, anorexia, depression and fever on physical examination sug‐
gest the presence of the disseminated form [42].
The diagnosis is based on clinical history, physical examination, cytological evaluation, fun‐
gal culture and histopathological findings [43]. Cytological evaluation usually reveals oval
to elongate yeast cells consistent with S. schenckii form and inflammatory cells may also be
present [45]. On histopathology, the presence of deep pyogranulomatous dermatitis, cellular
infiltration of polymorphonuclear and mononuclear cells, and the presence of PAS positive
structures compatible with S. schenckii may be observed [44]. Oral administration of itraco‐
nazole 10 mg/kg every 24 hours is the treatment of choice [46].
5.4. Cryptococcosis
Cryptococcus spp. is a saprophytic fungus present in the environment and in the feces of pi‐
geons, capable of causing systemic infection in dogs and cats, with a higher incidence in fe‐
lines. The species of interest in veterinary medicine are C. neoformans, which has a global
distribution and C. gattii that has a limited distribution [47]. C. neoformans typically infects
animals by inhalation and may cause ophthalmic, upper respiratory tract and central nerv‐
ous system lesions. Ulcerative lesions in the nasal, oral or pharyngeal mucosae, or a nasal
masse may be present (Figure 3) [31]. Mycotic rhinitis and cutaneous nasal bridge and nasal
plan involvement are the most frequent findings. In cats with positive serology for feline im‐
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munodeficiency virus (FIV) cryptococcosis tends to manifest itself in a disseminated or ad‐
vanced form [48].
Cryptococcosis diagnosis is based on fungal culture, cytological, histological and serological
exams [49]. Cytological examination may reveal the presence of leukocytes, macrophages
and numerous encapsulated structures (yeast) of different sizes (Figure 3) [50, 51].
Drug therapy leads to patient healing in most cases [49] and it consists of oral antifungal use
until complete remission of clinical signs, usually in 3 to 12 months. It is strongly recom‐
mended not to interrupt the treatment until the titers of antibodies against cryptococcosis
are reduced to zero [52]. Drugs commonly used include fluconazole 50 mg/cat every 12
hours [48] and itraconazole 50-100 mg/cat every 24 hours [52], or 10mg/kg for dogs and cats
every 24 hours [49]. Patients with nasopharyngeal masses benefit from surgical resection, for
upper airway patency and reduction of infected tissue to be treated medically [52].
Figure 3. Feline cryptococcosis. Figure on the left: a cat presenting a nasal masse (red arrow). Figure on the right: Cy‐
tology by fine needle aspirate of the nasal masse showing several encapsulated structures (yellow arrows) compatible
with C. neoformans (microscopic image viewed with a 100x oil objective).
6. Parasitic skin diseases
6.1. Demodicosis
Demodicosis is a very common skin disease in dogs but rare in cats [53]. It is an inflammato‐
ry disease, in which large amounts of Demodex mites are found in the skin [54]. Mites prolif‐
erate in the hair follicles and sebaceous glands causing the disease [55]. It is a common
condition and it is often serious in dogs. Besides Demodex canis, two less common species
were reported [54, 55], Demodex sp. cornei and Demodex injai [55]. Feline demodicosis may be
caused by two different kinds of mites, Demodex cati and Demodex gatoi [53].
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The mites are transferred from the mother to the offspring in the early life [56]. D. canis is
considered a commensal in canine skin. It is believed that this disease is a consequence of a
specific immunosuppression, which allows the proliferation of the mites [57]. Genetic fac‐
tors are probably very important in the development of generalized disease and therefore,
breeding of affected animals is contraindicated [54].
Erythema, comedones, scaling, partial or complete alopecia, papules, follicular casts, pus‐
tules, and in severe cases, furunculosis, crusting, exudation and ulceration with focal drain‐
ing tracts can be clinical sings. Generally the lesions begin on the face and limbs, but they
may become generalized. Demodicosis can be classified into generalized or localized. The
involvement of one complete body region, five or more focal areas, or the involvement of
the legs is considered generalized demodicosis. The diagnosis is made by deep skin scrap‐
ings or trichogram. In some rare cases, in the legs or certain breeds such as Shar-peis, these
tests may be negative, requiring biopsies for mite detection [58].
In most dogs, localized demodicosis resolves spontaneously, thus mite-specific therapy is
not necessary until the disease generalizes [53]. The treatment of generalized demodicosis
involves several approaches. In addition to the acaricidal treatment, the concurrent secon‐
dary  infections  and  underlying  diseases  should  be  also  accessed  [58].  As  an  acaricidal
treatment, ivermectin is recommended at 0.3 to 0.6 mg/kg orally once a day, however, it is
recommended  to  begin  the  treatment  with  a  lower  dose  and  gradually  increase  the
amount of drug administered. The animal should be monitored for the appearance of ad‐
verse effects. Therapy with moxidectin 0.2-0.5 mg/kg orally once a day and doramectin 0.6
mg/kg orally  or  subcutaneously  once  a  week were  proven effective  in  the  treatment  of
generalized demodicosis. The same careful institution of a gradual dose taken with iver‐
mectin should be applied for these two other drugs. Milbemycin oxime can also be used
at 1 to 2 mg/kg orally, once a day, with good results [58]. In cats weekly baths with 2%
lime sulfur are indicated for the treatment of demodicosis. There is remote evidence to in‐
dicate weekly application of 0.025% amitraz and for the use of doramectin 0.6 mg/kg once
a week subcutaneously [53].  Treatment should continue for  one month after  getting the
third consecutive negative scraping [58].
6.2. Canine scabies
Canine scabies is a common condition in dogs and humans, but rare in cats, in which the
skin is colonized by Sarcoptes scabiei mite after contact with a donor host. The infestation
with this mites results in intense pruritus [59, 60]. Female mites dig galleries in the stratum
corneum in order to lay their eggs that hatch, releasing larvae forms that migrate to the skin
surface, where they reach the adult stage [61].
Extremely  irritating  and  pruritic  papular  eruption,  skin  thickening,  erythema,  alopecia,
exudation with crust formation and secondary bacterial infection with pustules are com‐
mon clinical  findings (Figure 4).  Chronic  lesions are  usually confined to the margins of
the pinna,  elbows and hocks that may present skin thickening,  minimal crust formation
and persistent pruritus [61].
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Skin scraping with microscopic identification of S. scabiei is a valuable diagnostic method,
although mites are hardly seen in many cases. Diagnosis is usually based on the animal’s
history,  clinical  signs  and  a  positive  pinnal-pedal  reflex  (pinna  margings  are  gently
scratched and the dog will reflexively use an ipsilateral hind limb to scratch the source of
the irritation) [62, 63].
The treatment is recommended to the patient and other animals in their household. Bathing
with 0.025% amitraz solution once weekly or twice weekly is recommended as an effective
treatment. The therapy should be continued for two weeks after clinical signs remission. Ad‐
verse side effects should be monitored during the treatment [64]. Fipronil spray 0.25% can
be applied three times with three weeks intervals on puppies [65]. Ivermectin can be admin‐
istered at 0.2 to 0.4 mg/kg, orally every seven days, or subcutaneously every 14 days. The
treatment usually takes four to six weeks [66].This drug is contraindicated in Collies and
their crosses [67]. An effective alternative treatment of scabies is a spot-on application of se‐
lamectin at 6-12 mg/kg every 15 to 30 days, for at least three applications and it is apparent‐
ly, well tolerated in different breeds [67, 68]. Milbemycin oxime at 2mg/kg in a weekly dose,
administrated for up to five times has also a good efficacy [69].
NOTE: The permission for the use of macrocyclic lactones in the treatment of cats and dogs
is different for each country. The rules concerning its use should be checked before treat‐
ment institution and the owners must be warned in order to authorize any extra-label use of
these medications.
Figure 4. Scabies. Figure on the left: a dog with erythematous, alopecic and lichenified pruritic lesions in the distal
aspect of the hind limbs. Figure on the right: the animal's owner presenting abdominal pruritic papular lesions, high‐
lighting the zoonotic aspect of scabies.
Dermatology in Dogs and Cats
http://dx.doi.org/10.5772/53660
11
7. Allergic diseases
7.1. Flea allergy dermatitis
Ctenocephalides felis felis is the most important ectoparasite in dogs and cats in several coun‐
tries [70]. Its infestation may cause intense pruritus, self-inflicted trauma and even severe
symptoms as anemia. Some animals will develop a severe condition known as flea allergy
dermatitis (FAD). After the sensitization, the lesions may be initiated by only a few flea bites
[71]. Flea allergy is one of the most frequent conditions in dogs, especially in humid and
warm weather countries, where fleas are commonly found [72]. The most common clinical
signs are erythema, excoriation, crusting, and pustules that usually affect the medial caudal
aspect of forelegs and ventral abdomen; pyotraumatic dermatitis may also be observed [73].
Diagnosis is based on circumstantial evidence, such as clinical response to flea control. A
successful treatment for FAD depends on eliminating the allergy source, the flea. Therapy
goals are the total elimination of flea population in the patient’s body and environment, as
well as in contact animals. It is also important to prevent new infestation, what is not always
simple, once fleas have a high reproductive capacity and a complex life cycle [71]. Flea con‐
trol advances with modern insecticides and insect growth regulators markedly decreased
the number of affected animals. Products as fipronil, imidacloprid, metaflumizone, nintem‐
piram, selamectin e spinosad proved to be efficient to control fleas in animals with FAD [74].
These products are available in several presentations as shampoo, collars, spray, powder,
spot on and oral medication [71].
7.2. Adverse food reaction
Adverse food reactions are described in veterinary medicine since 1920, reporting the occur‐
rence of gastrointestinal signs and skin reactions in response to food allergens [75]. Adverse
food reaction refers to any abnormal clinical response assigned to consumption of food or its
additives [76]. This reaction is classified as food allergy (immune-mediated) or food intoler‐
ance (non-immune-mediated). The majority of reactions in animals are food intolerances
and they can be of pharmacological or metabolic origin, poisoning, idiosyncrasy [76, 77],
toxicity or anaphylactic reaction to the food [77]. There are some dogs with pruritic skin dis‐
eases or otitis which resolves with restrictive diet, but it remains unproved the immunologic
cause or hypersensitivity (allergy) associated with cutaneous adverse food reactions
(CAFR). Once the etiopathogenesis was not elucidated yet, the term food allergy should be
avoided, and CAFR is more appropriate [76, 78]
There are no breed, sex or age predisposition to the occurrence of clinical signs. Pruritus is
the most important sign reported and it affects mainly the face, perineum and ears (otitis ex‐
terna). Gastrointestinal signs as vomiting and diarrhea can also be observed. The best diag‐
nostic approach for CAFR in dogs and cats is feeding them with a diet, with only one source
of protein that the animal has never been in contact before (novel protein). The diagnosis is
obtained with the resolution of clinical signs after the diet trial and with the return of these
signs when the previous diet is offered again. The diet trial should be implemented for at
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least six weeks. Homemade diets are more appropriate for the CAFR trial described above,
but there are also commercially available prescription and hydrolyzed diets [75].
Prescription diets, commercially available in some countries, are made of an unusual protein
source and a non-allergenic carbohydrate source such as potato or oat meal. Lamb, duck,
rabbit and Kangaroo meat are protein sources usually found in these diets [77]. Another op‐
tion considered really hypoallergenic is the hydrolyzed diet. For humans it is known that
most food allergens are glycoproteins with molecular weight higher than 12,000 d. The hy‐
drolyzed food has smaller peptides what makes them potentially less allergenic [75]. How‐
ever, a small percentage of allergic dogs show poor response to hydrolyzed food. The
possibility of adverse food reaction to hydrolyzed food in sensitive dogs is rare but should
be considered [79].
CAFR differential diagnoses are other hypersensitivities as FAD, atopic dermatitis, diseases
caused by ectoparasites, and yeast or bacterial infections. These infections can also appear as
complications of a pruritic process. Therapy should include secondary infections and otitis
externa. Some cases also demand severe pruritus control while the diet trial is applied. Any
drug therapy should be interrupted at least three weeks before the end of the diet trial, so
that the clinician can access the animal response to the diet [75]. It is still unknown if ani‐
mals develop tolerance to food allergens after a long period without contact, as reported in
humans, however, natural hyposensitization is apparently rare [77].
7.3. Atopic dermatitis in dogs
Canine atopic dermatitis (CAD) is an allergic, hereditary, inflammatory and pruritic skin
disease, with characteristic clinical signs associated with immunoglobulin E (IgE) produc‐
tion against environmental allergens [80]. Atopic dermatitis also affects cats, but its inci‐
dence is lower than in dogs [81].
Most dogs with atopic dermatitis begin to manifest signs between six months and three
years of age [82, 83]. There is no sex predisposition and clinical signs may or not be seasonal,
depending on the allergen involved. Usually, patients have a history of pruritus with or
without secondary skin or ear infections. Primary lesions include macules and papules, but
frequently, patients are presented with secondary lesions from self-inflicted trauma as ex‐
coriations, alopecia, lichenification and hyperpigmentation. Lesions affect the face, concave
part of the pinna, ventral aspect of the neck, axilla, groin, abdomen, perineum, ventral as‐
pect of the tail, limbs joints, medial aspects of limb extremities, feet and ears [85].
In dog as in human beings there is no pathognomonic sign of atopic dermatitis that could
provide a diagnosis based only in history and physical examination. Diagnosis depends on
patient fitting in several criteria associated with the condition and on elimination of differ‐
ential diagnoses. Following clinical diagnosis, laboratory or clinical tests as allergy tests and
histopathology, reinforces the diagnosis. However, these tests should not be used to estab‐
lish the diagnosis but to confirm it [82]. It is important to highlight the fact that some dogs
with inflammatory and pruritic skin diseases, displaying clinical signs identical to those
found in CAD, may have no IgE production in response to environmental allergens. This
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condition is known as “canine atopic like dermatitis” [80]. Other dermatosis might share
similar signs with canine atopic dermatitis or could be concurrent diseases and it is why
they should be eliminated or controlled before the conclusive diagnose of CAD. Differential
diagnoses for CAD are FAD, CAFR, pruritic parasitic diseases, bacterial pyoderma, Malasse‐
zia dermatitis and other allergic diseases [82, 83]. Allergy tests goals are to determinate aller‐
gens, to contact avoidance and to be included in the allergy specific immunotherapy [83].
No allergy test is completely sensitive or specific, therefore, clinically normal animals can
have positive responses and animals with negative results can have clinical characteristics of
the disease [82]. Allergens generally related to CAD pathogenesis are domestic dust mites,
mold spores, trees and grasses pollens, antigens from insects and epidermis [84].
Atopic dermatitis is one of the most common skin diseases in dogs, however, its pathogene‐
sis is not completely understood, so there is no curative therapy available yet [85]. Diverse
topical and systemic therapies are currently available for CAD treatment such as specific al‐
lergy immunotherapy, corticosteroids, calcineurin inhibitors, anti-histamines and essential
fatty acids. Unfortunately, these therapies are not effective in all cases or show adverse ef‐
fects with long term use [86]. For most dogs with atopic dermatitis, the elimination or pre‐
vention of the contact with allergens is extremely difficult and drug therapy is not always
satisfactory, in these cases the possibility to modulate the immune response to allergens is a
good option. Specific allergy immunotherapy, also known as hyposensitization, desensitiza‐
tion or allergy vaccines [85], is defined as the act of administrating increasing amounts of
allergen extracts to an allergic patient, in order to minimize the symptoms related to aller‐
gen exposure. Immunotherapy is not an option for patients that do not produce IgE against
allergens with clinical relevance [87]. As a result, 50 to 100% of dogs submitted to immuno‐
therapy may show improvement in clinical signs after four months of treatment, and some
of these animals remain with no clinical sign for long periods [88]. Despite broadly applied
in the treatment of human atopic dermatitis, there are just a few studies of the topical corti‐
costeroids use in veterinary medicine. Triamcinolone 0.015% spray was used with good re‐
sults during a month with minimal side effects [89]. Recently, hydrocortisone aceponate
0.0584% spray applied once daily in affected areas, in the dose of two sprays for each 100
cm2, during 84 days was markedly effective, showing results similar to those obtained with
cyclosporine therapy, although with no adverse effects [90]. Frequently used oral glucocorti‐
coids are prednisone, prednisolone and methylprednisolone, considered efficient and with
rapid anti-allergic effect, at 0.5 to 1.0 mg/kg once or twice daily. Once desired effect is ach‐
ieved, the dose may be decreased maintaining efficiency. Often observed adverse effects are
related to dose and duration of the treatment [89]. Calcineurin inhibitors as tacrolimus 0.1%
ointment applied twice daily on localized lesions is efficient in CAD treatment [91]. Good
efficacy can also be observed with oral cyclosporine 5 mg/kg once daily during four to six
weeks. When using cyclosporine the dose is usually reduced to half after obtaining improve‐
ment in clinical signs, maintaining the efficiency. Side effects as vomiting and transient diar‐
rhea can occur. Oral anti-histamines has been used for decades in CAD treatment, however,
there is no study showing conclusive evidences of its efficacy. Adverse effects of anti-hista‐
mines may be sedation and lethargy but this signs are uncommon. Omega 3 and 6 essential
fatty acids from vegetal or from fishes source has been used for longer than 20 years in the
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treatment of atopic dermatitis. They are commercially available in capsules, liquid or en‐
riched diet. The benefits of fatty acids therapy for CAD, is not clear despite the many studies
in the area, however, they might reduce the corticosteroids dose, after 8 weeks of concurrent
therapy [89].
8. Immunologic skin diseases
8.1. Pemphigus complex
Pemphigus complex diseases result from the production of autoantibodies directed against
epidermal intercellular content, resulting in cell separation with intraepidermal bullae for‐
mation. The deposition of antibodies promotes the physical separation of the cells; more‐
over, it is believed that the release of cell proteases occur, which digests the intercellular
substance, further aggravating the condition. Among the forms observed in dogs and cats
are pemphigus erythematosus, pemphigus vulgaris, pemphigus vegetans and pemphigus
foliaceus, the latter being the most common autoimmune skin disorder in these species [92],
which will be discussed in this chapter.
Pemphigus foliaceus is observed more frequently in middle-aged animals, especially in do‐
mestic short haired cats and in dogs of some predisposed breeds such as Bearded Collies,
Japanese Akitas, Chow Chows, Doberman Pinschers and Newfoundlands [93, 94]. It is a
vesiculobullous, erosive disorder, which produces evident footpad hyperkeratosis. The face,
trunk and abdomen are also frequently affected [95, 96]. Pustules, crusted lesions, erythema,
alopecia and secondary pyoderma may also be present [94, 96]. Cachexia and sepsis secon‐
dary to infection may be observed in severe cases [97].
When present, pustular lesions can be evaluated cytologically and can reveal non degen‐
erated granulocytes and acanthocytes [94].  Histologically intraepidermal and intrafollicu‐
lar  pustules  are  observed,  with  the  presence  of  superficial  perivascular  dermatitis  and
acanthocytes  [92,  93,  98].  The histologic  presence of  acantholysis  is  the Hallmark of  the
pemphigus complex [98].
Therapy requires the use of immunosuppressant or immunomodulators. Prednisone, pre‐
dnisolone and methylprednisolone are commonly used in the treatment of pemphigus. Ini‐
tially it is recommended a dose of 2.2 to 4.4 mg/kg, every 24 hours, for all three drugs. If
therapeutic response is seen in 14 days, the dosage should be reduced gradually over 30 to
40 days. After this, an alternate day dose should be implemented, reaching a final protocol
of 1 mg/kg every 48 hours or less [98]. In resistant cases of canine pemphigus, the use of pre‐
dnisolone can be combined with azathioprine (2.2 mg/kg q12h or q24h) or cyclophospha‐
mide (50 mg/m2 q48h). Feline pemphigus normally responds well to prednisolone, although
resistant cases may benefit from a combination of prednisolone and chlorambucil (0.1-0.2
mg/kg every 24 hours or every other day) [94]. Topical glucocorticoids can be used as a sin‐
gle therapy, in localized forms of pemphigus or used for persistent lesions, as adjunctive
therapy to the systemic treatment [98]. The occurrence of deaths in cases of pemphigus folia‐
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ceus are mainly from side effects of the drugs, secondary infections or in many cases, the pet
owner requests euthanasia [97].
8.2. Discoid lupus erythematosus
Discoid lupus erythematosus (DLE) is an immune-mediated disease in which the lesions are
similar to those of systemic lupus erythematosus (SLE), although, without the presence of
the fluorescent antinuclear antibody and without the involvement of other body systems, as
occurs in SLE [99]. The etiology is unknown, however, sunlight can precipitate or exacerbate
the lesions. The most commonly affected regions of the body are the face and ears. Initially,
there are depigmentation, erythema and desquamation. The lesions progress to scaly and
swollen plaques. Definitive diagnosis is made by characteristic histopathology or immuno‐
fluorescence. Affected animals usually have a good response to systemic therapy with glu‐
cocorticoids, but topical presentations are also an option to the treatment [100]. Topical
tacrolimus 0.1% can be an alternative therapy to the treatment with glucocorticoids, and was
effective and safe for the treatment of DLE in dogs [101].
9. Metabolic and endocrine diseases
9.1. Hypothyroidism
Hypothyroidism is an endocrine disorder associated with a reduced production of T4 and
T3 hormones by the thyroid gland [102]. Rarely affects cats [103], however, is the most com‐
mon endocrinopathy in dogs [104]. The primary destruction of the thyroid gland occurs in
more than 95% of adult dogs with hypothyroidism [104,105]. Thyroid hormones are ex‐
tremely important in the maintenance of normal skin function, and dermatologic conditions
are reported in 60 to 80% of hypothyroidism cases [106,107]. Usual findings are changes in
coat quality and color, alopecia (in most cases, bilaterally symmetric and sparing head and
limbs), superficial pyoderma, dry and desquamated skin, dry or oily seborrhea, brittle and
easily pulled hairs, hyperkeratosis, hyperpigmentation, comedones, otitis, deficient healing
of wounds, pruritus, myxedema and obesity [108].
Diagnosis is based on clinical signs, and on serum total TSH and free T4 [109]. Histopatholo‐
gy may show highly suggestive signs of hypothyroidism as follicle atrophy, hyperkeratosis,
epidermal melanosis, many follicles in telogen phase [110], hypertrophy and vacuolization
of arrector pili muscles, increased dermal mucine and thickened dermis [111].
Oral sodium levothyroxine (T4), 20 µg/kg twice daily, is the drug of choice for hypothyroid‐
ism [108]. The patient should receive appropriate treatment for dermatologic conditions pre‐
sented, although they tend to disappear with the sodium levothyroxine administration.
9.2. Hyperadrenocorticism
Hyperadrenocorticism, also known as Cushing syndrome, results from chronic excessive
cortisol secretion by the adrenal glands. It occurs iatrogenically, after synthetic glucocorti‐
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coids administration, or spontaneously, as a consequence of pituitary or adrenal gland pri‐
mary hyper function. In dogs and cats, 80 to 85% of spontaneous hyperadrenocorticism are
hypophysis-dependent [112]. Poodles, Dachshunds, Boston Terriers and Boxers are the more
often affected dog breeds, and it rarely occurs in cats [113].
Symptoms as polyuria, polydipsia, polyphagia, hepatomegaly and abdominal swelling (pot-
bellied appearance) are commonly observed. Dermatological signs include hypotrichosis,
alopecia along the back tending to be symmetrical and bilateral, comedones, pyoderma and
seborrhea [112]. Hyperpigmentation, thinner skin and calcinosis cutis occurs less frequently
[114]. Clinical signs associated to laboratorial evaluation and diagnostic imaging findings,
leads to the diagnosis. Plasma ACTH, low dexamethasone dose suppression test, ACTH
stimulation test [113, 115] and urinary cortisol/creatinin ratio [116] confirms hyperadreno‐
corticism. It is also important to obtain the history of glucocorticoids use to eliminate iatro‐
genic cause [117].
Hyperadrenocorticism therapy depends on etiology, severity degree, tumor malignancy and
availability of treatment options [118]. In hypophysis-dependent cases of adrenal dysfunc‐
tion, surgical resection of the pituitary gland can be performed with low mortality rate.
Adrenalectomy is recommended in cases of adrenal neoplasms. Drug therapy to control hy‐
percortisolism involves the oral use of mitotane (o, p'-DDD), 50 mg/kg once a day [113] or
oral trilostane, 2 to 3 mg/kg once a day. Some dogs may show a transient worsening of der‐
matological signs, especially with mitotane use. Complete resolution of dermatological signs
usually takes months to be achieved [118].
10. Acquired alopecia
10.1. Canine pattern baldness
Canine pattern baldness is a common condition that affects short coated dog breeds with the
development of acquired alopecia in specific body regions as, post-auricular, ventral cervi‐
cal, chest, abdomen and caudomedial aspect of the thighs [119] (Figure 5). Canine pattern
baldness is an aesthetic problem, with no consequences to patients health however, treat‐
ment may be required by the owners. Treatment may be tried with oral melatonin 5 mg (one
capsule), once daily during 30 days to promote hair growth in alopecic regions [119,120].
10.2. Canine follicular dysplasia
Follicular dysplasia is an inherited condition characterized by an abnormal development of
the hair follicle, leading to hair structural abnormalities and alopecia [121]. Neck, back and
hind limbs can be affected and secondary pyoderma and comedones are common clinical
findings [122]. The diagnosis confirmation through histopathology revel a great number of
dysplastic follicles, dysplastic hair shafts and melanin aggregates within the hairs [123]. Pa‐
tients can experiment spontaneous remission of follicle dysplasia, however, oral administra‐
tion of 3 mg melatonin twice daily may help hair regrowth [124].
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Figure 5. Canine pattern baldness. A Doberman pinscher with alopecia of the chest, which is characteristic of pattern
alopecia (Veterinary Hospital of the Federal University of Viçosa).
10.3. Post clipping alopecia
Post clipping alopecia or post clipping hair follicles arrest [125] is a common but poorly un‐
derstood syndrome in dogs, characterized by the absence of hair in consequence to a defi‐
cient growth in a previously clipped area [126]. In some cases the hair may take years to
grow back. On clinical exam, the skin is normal with well delimited alopecic areas. Diagno‐
sis is closed by the history of alopecia after clipping with no other dermatologic sign. If any
systemic sign or other skin disorders are present, it is recommended to perform appropriate
laboratory procedures to search for the endocrinopathies [125]. Usually no treatment is re‐
quired [122]
10.4. Alopecia X
Alopecia X is a disease previously known as adrenal congenital hyperplasia, Cushing-like
disease, dermatosis responsive to castration and adult-onset hyposomatotropism [127]. It is
a condition associated with abnormalities on the hair cycle, affecting mainly the German
Spitz breed. Affected animals display hairs in telogen phase what prevents new hair growth
[128]. These animals are clinically healthy and show progressive hair loss, symmetric and
non-pruritic, with variable degree of hyperpigmentation [129]. Histopathology findings are
similar to those found in endocrinopathies, such as comedones, superficial and infundibu‐
lum hyperkeratinization, however, the presence of catagenization with flame follicle forma‐
tion, confirms alopecia X diagnosis [127].
Therapies with sex hormones, growth hormone, mitotane and castration usually do not pro‐
duce consistent results. Trilostane 10.5 mg/kg once a day, or twice a day, may produce com‐
plete hair growth in affected animals after four to eight weeks of treatment [129].
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11. Keratinization disorders
11.1. Seborrhea
Seborrheic dermatitis is a skin keratinization disorder which can be primary or secondary.
Primary keratinization disorders are inherited and exhibits breed predisposition. Usually,
clinical signs appear before two years of age [130]. About 90% of the cases are secondary to
an underlying disease [131,132] such as metabolic, hereditary or nutritional disorders [133]
that causes excessive skin desquamation [131,132].
Seborrhea is classified in seborrhea sicca or oleosa according to hair and skin appearance
[131,132]. In seborrhea sicca the coat is opaque and dry, containing aggregates of white to
greyish scales, and in seborrhea oleosa there are adhesions of yellowish to brown lipid mate‐
rial, with greasy appearance [130]. Animals often exhibit pruritus, folliculitis, pyoderma, in‐
flammation and hyperkeratosis plaques formation [131,132].
Diagnosis is based in history, clinical signs, physical examination findings and complemen‐
tary exams to eliminate differential diagnosis or to determinate the primary disease. Fre‐
quently, it is necessary to perform skin scrapings, fungal and bacterial cultures, allergy tests,
endocrine function evaluation, skin biopsy and evaluation of therapy response to close the
diagnosis. Histopathology reveals abnormal keratinization of the epidermis and hair folli‐
cles, orthokeratotic and parakeratotic hyperkeratosis, follicular hyperkeratosis, dyskeratosis
and perivascular superficial dermatitis [130].
Seborrhea treatment goals are scales and crusts removal and oil, pruritus and inflammation
reduction [131,132]. Cases of primary idiopathic seborrhea could be treated with oral Vita‐
min A (600 to 800 UI/kg, twice daily) or with retinoids as isotretinoin and etretin (1 a 2
mg/kg a q12h) [134]. Salicylic acid and sulfur shampoos are recommended and might have
positive results in moderate cases. Tar shampoos are recommended to severe cases of sebor‐
rhea oleosa in dogs, however, they are contraindicated in cats [135]. Secondary cases have
an excellent prognosis when the underlying disease is eliminated, while primary keratiniza‐
tion disorders demand lifelong control and treatment [130].
11.2. Acne
Acne is a common disorder in cats and it may result from an idiopathic keratinization defect
or a secondary reaction pattern to another disorder [136]. The most common skin changes
are found in the chin and lip margin, and they include comedones, crusts, papules, erythe‐
ma, alopecia and variable pruritus. Usually this disorder courses with secondary bacterial
pyoderma and in some cases, with M. pachydermatis infections [137]. Papules, pustules, fu‐
runculosis and cellulitis might be signs of a secondary infection. Changes in hair follicle cy‐
cle, immunosuppression, stress, deficient grooming and concurrent viral infections are
possible causes for this disorder [136]. Histology shows periductal linfoplasmocitary inflam‐
mation, sebaceous gland duct dilatation and follicular keratosis with obstruction and dilata‐
tion of the follicles [137]. Mild cases can be treated with anti-seborrheic shampoo; however,
severe cases require association with systemic antimicrobial therapy or systemic corticoids
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[136]. Mupirocin 2% ointment is efficient when applied on lesions twice daily [138]. Topical
tretinoin 0.01 to 0.025% (lotion or ointment) improves the clinical signs in chronic cases
[139,140]. Proper recognition and treatment of secondary infections contribute to a success‐
ful therapy [137]. Feline acne has a good prognosis, however, symptomatic lifelong treat‐
ment is often necessary to control the condition [140].
12. Psychogenic diseases
12.1. Acral lick dermatitis
Acral lick dermatitis is characterized by ulcerated, proliferative, firm and alopecic plaques,
derived from compulsive licking of the distal portion of the limbs [141] (Figure 6). Secon‐
dary bacterial infection is frequent and contributes to the sorely pruritic nature of the lesions
[142]. This condition may originate from psychogenic (fear, and/or anxiety-based condi‐
tions), dermatologic (secondary to hypersensitivity, demodicosis, neoplasms and fungal or
bacterial infections), traumatic, neuropathies or articular diseases [141,142].
Diagnosis requires complete clinical evaluation (anamnesis, physical, neurological and der‐
matological exams), complete blood cell count, serum biochemical profile and urinalysis.
Only after the elimination of possible organic causes for acral lick dermatitis, it can be con‐
sidered a behavioral disorder. In this case, the animal behavior should be evaluated, with
the observation of its environmental and social stimuli and their motivational status. Treat‐
ing acral lick dermatitis is notoriously challenging. The animal’s environment should be
modified to eliminate or minimize their exposure to stress factors [142], and the use of anti-
depressives as fluoxetine 20 mg/day may help significantly in compulsion control which im‐
proves the lesions [143].
Figure 6. Acral lick dermatitis. Ulcerated plaques with tissue necrosis in the distal potion of a dog’s forelimb.
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13. Nutritional skin diseases
13.1. Vitamin A responsive dermatosis
Vitamin A is essential to the maintenance of epithelial tissue integrity and is especially im‐
portant in the keratinization process [144]. Vitamin A responsive dermatosis is an uncom‐
mon condition, observed mainly in properly fed Cocker Spaniels [145] that may exhibiting
skin desquamation, pruritus, oily skin, characteristic hyperkeratotic plaques and secondary
pyoderma [144]. Histopathology reveals follicular oriented exuberant hyperkeratosis [145].
Lesions do not improve with anti-seborrheic therapy, but oral supplementation of vitamin A
(retinol), at 10.000 UI once a day, provides clinical improvement in 5 to 8 weeks of treat‐
ment. Lifelong treatment is usually necessary [144].
13.2. Zinc responsive dermatosis
Zinc is essential in the cellular metabolism and also in hair and skin health maintenance
[144]. Zinc responsive dermatosis is an unusual disorder in dogs and it is characterized by
scaling, focal erythema, crusts and alopecia, mainly over the head [146].
Two syndromes are recognized in dogs. Syndrome I affect young adult dogs fed with bal‐
anced diets, especially Siberian Huskies and Alaskan Malamutes, however, it was reported
in other breeds [146,147]. Affected animals have a diminished ability to absorb zinc from the
intestinal tract, due to some subclinical disease or to genetic factors [144]. Syndrome II is ob‐
served in rapidly growing puppies, especially of giant breeds, fed with zinc deficient diets
or with excessive calcium phytate [144,146].
The diagnosis is based on history, clinical signs, characteristics lesions, breed, skin biopsy
and response to zinc supplementation. The histopathological abnormalities found are papil‐
lary epidermal hyperplasia, confluent spongiotic parakeratosis and suppurative crusts [146].
Syndrome I control requires lifelong oral zinc supplementation with zinc methionine 1.7
mg/kg once a day, zinc gluconate 5 mg/kg once a day or zinc sulfate 10 mg/kg once a day
[14]. Refractory cases to oral supplementation could receive intravenous administration of
zinc sulfate at 10 to 15 mg/kg once a week, initially during four weeks and later each one, to
six months [144]. Prognosis is good in most cases, although, lifelong supplementation may
be required. Affected animals should be removed from breeding [147].
Syndrome II has an excellent prognosis and only requires food balancing to supply the zinc
deficiency, however, signs remission occur faster with oral zinc supplementation [144].
13.3. External ear diseases
The external ear is divided in three parts: inner, middle and outer ear. External or outer ear
comprises the pinna, vertical canal and horizontal canal, formed by auricular and annular
cartilages. The diameter of the external ear canal varies according to the age, breed and size
of the animal and it is separated from the middle ear by the tympanum, a thin semitranspar‐
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ent membrane with an elliptic shape [148]. External ear diseases are particularly important
in veterinary dermatology, since the outer ear is formed in the embryo life through a skin
invagination, being susceptive to a number of dermatologic conditions [149]. Otitis externa
is the most frequent disorder of the outer ear canal in dogs and cats, consisting in the inflam‐
mation of its epithelium [150,151].
In order to achieve the correct diagnosis and a successful therapy, it is essential to recognize
and understand the primary predisposing and perpetuating causes. Primary causes are fac‐
tors or processes that trigger the inflammation in the outer canal [152]. The most frequent
trigger factors are parasitic infestation (Octodetes cynotis, Demodex canis, Sarcoptes scabiei, No‐
troedes cati), foreign body, allergic diseases and hypersensitivities (atopic dermatitis, food al‐
lergy, contact allergic dermatitis), keratinization disorders (seborrhea, sebaceous adenitis),
hormonal disorders and autoimmune diseases (pemphigus, lupus erythematous). Predis‐
posing causes are factors and process that increases the risk of otitis development, such as
the ear conformation (narrow ear canal, excessive hair in the ear canal, long and pendulous
ears), excessive humidity (baths, swimming habit), iatrogenic factors (use of cotton swab to
clean the ear, use of irritant cleaning solutions) and the occurrence of obstructive ear diseas‐
es (polyps and neoplasms) [151].
Factors  that  help  to  perpetuate  otitis  are  bacterial  infection  (Staphylococcus  pseudinterme‐
dius,  Pseudomonas aeruginosa),  yeast infection (M. pachydermatis)  and complications of oti‐
tis  media,  as  ear  canal  narrowness  due  to  hyperplasia  and calcification  of  the  cartilage
structures [151,153,154].
The initial sign of otitis externa is erythema of the pinna and outer ear canal. Worsening of
symptoms can lead to head shake, ear pruritus, malodorous purulent or ceruminous dis‐
charge, edema, pain and evidences of self-inflicted trauma as aural hematoma and acute
moist dermatitis in the base of ears. Chronic or recurrent otitis can lead to soft tissue hyper‐
plasia, ear canal stenosis and occlusion [151].
Diagnosis requires physical and dermatological examination, knowledge of the dermatolog‐
ical history and clinical signs development. Otoscopic examination is the first choice techni‐
que to evaluate the outer ear canal [155] and it should be performed in every patient with
signs of otitis [156]. It is important to notice that a healthy ear canal might have small
amounts of yellowish or brown cerumen [150]. Through otoscopy the clinician can access
the presence of inflammation, exudate, hyperplasia, stenosis, foreign body, neoplasms and
evaluate the tympanic membrane. Depending on the degree of pain, inflammation and
stenosis, it might be necessary to use topical or systemic corticoids for two to three weeks
before performing an otoscopic examination [156].
Cytological analysis is  required for the diagnosis,  and samples should be obtained from
both pinna and the outer vertical and horizontal canal. Cytology can provide early infor‐
mation about  the inflammatory response and microbial  organisms or  parasites  involved
in the process [150].
A successful therapy is based on: removing or controlling the primary cause and predispos‐
ing factors; eliminating bacterial and yeast infection, parasite infestation and foreign bodies
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on ear canal; cleaning the pinna, vertical and horizontal canal; eliminating debris, exudates
and cerumen. It is also extremely important to instruct the owner about cleaning techniques
and administration methods for topical medications [150].
Gram positive bacterial infections can be treated with topical steroidal antibiotics (fusidic
acid) and topical fluoroquinolones (marbofloxacin and orbifloxacin). Gram negative infec‐
tions could also be treated with fluoroquinolones or with topical cationic polipeptides (poly‐
myxin B) and aminoglycosides (neomycin, framycetin, gentamicin) [154]. Aminoglycosides
are contraindicated in cases of tympanic membrane rupture due to their ototoxicity [150].
Malassezia species are usually susceptible to azoles (clotrimazol and myconazol) and poly‐
ene macrolides (nistatin) [154].
The use of topical drugs such as moxidectin 1% and imidacloprid 10% (0.1 mg/kg, two ap‐
plications with two weeks interval) is effective for Otodectis cynotis infestation in cats [157].
Animals with acute otitis should be treated twice daily during 7 to 14 days. Chronic or re‐
current cases should be treated for, at least 4 weeks, and systemic anti-inflammatory drugs
are recommended in association to the topical therapy (prednisone or prednisolone 0.5
mg/kg q12h) [158]. Glucocorticoids efficiently control the inflammation and may prevent or
reverse tissue hyperplasia and canal stenosis [154].Therapy should be discontinued only
when cytology is negative for microorganisms, if there is no ear canal edema and if the epi‐
thelium has a normal appearance [158].
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